本公司的本次公司通訊備有中、英文版本，並已上載於本公司網站 www.grandpharma.com 及香港交易所披露易（「披露易」）網站 www.hkexnews.hk，歡迎瀏覽。 若 閣下已選擇收取本公司的公司通訊（「公司通訊」） （附註） 之印刷本，則隨函附奉 閣下所選擇之本次公司通訊印刷本。 閣下若因任 何理由以致在收取或接收載於本公司網站上的本次公司通訊出現困難，本公司將於接到 閣下通知後，盡快向 閣下免費發送有關本 次公司通訊的印刷本； 閣下可以書面方式通知本公司的香港股份過戶登記處（「股份過戶處」）香港中央證券登記有限公司，地址為 香港灣仔皇后大道東 183 號合和中心 17M 樓，或電郵至 grandpharma.ecom@computershare.com.hk。 閣下有權要求更改所選擇收取日後公司通訊的收取方式，請填妥隨附之回條（「回條」），然後以專人交付或使用回條底部隨附的郵寄標 籤將回條寄回股份過戶處（如在香港投寄，毋須貼上郵票；否則，請貼上適當的郵票）； 閣下亦可把已填妥及簽署回條的掃描副本以 電郵方式發送至 grandpharma.ecom@computershare.com.hk。 ...

(Incorporated in Bermuda with limited liability) ( 於百慕達註冊成立之有限公司 ) (Stock Code 股份代號: 00512) 各位登記股東： 徵集電子聯絡資料 為確保及時收到最新的公司通訊，本公司建議 閣下透過掃描隨附之回條上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。 或者， 閣下也可以簽署回條並交回股份過戶處。 如果本公司沒有收到 閣下的有效電子郵件地址，直至股份過戶處收到 閣下有效的電子郵件地址前， 閣下或將(i)無法收到任何有 關發布公司通訊的通知；(ii)需要主動查看本公司網站和披露易網站以留意公司通訊的發布 ；及(iii)本公司未來將以印刷本形式發送可 供採取行動的公司通訊 （附註 2） 。 若 閣下希望收取 未 來 公司通訊之印刷 本 ， 請 填妥隨附之回條並交予 股份過戶處 或 發 送 電 子 郵 件 至 grandpharma.ecom@computershare.com.hk，並註明 閣下的姓名、地址以及收取公司通訊印刷本的要求。請注意，收取未來公司通訊印 刷本之指示由收悉 閣下指示當日起計一年內有效，此後將過期。 如 閣下對 ...

Core Insights - The announcement from Yuan Da Pharmaceutical regarding the new specification (20ml: 50mg) of its drug, Qufei Lianer injection, received approval from the National Medical Products Administration on September 22, indicating a significant development in the treatment of pulmonary arterial hypertension (PAH) [1] - Qufei Lianer injection is the only drug in China that can be administered subcutaneously and intravenously for PAH treatment, which is a first-line medication and a foundational drug in targeted therapy regimens [1][5] - The PAH market is projected to grow significantly, with an estimated global market size of approximately $8.06 billion in 2024, expected to reach around $13.5 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.3% [5] Company Insights - Qufei Lianer is a synthetic prostacyclin analog that promotes vasodilation and inhibits platelet aggregation, effectively treating PAH symptoms [5] - The drug has demonstrated long-term efficacy and safety in clinical studies, with one-year and four-year survival rates of 88% and 70%, respectively, indicating a significant improvement in patient prognosis [5] - The sales revenue of Qufei Lianer has consistently exceeded $100 million annually, achieving approximately $517 million in global sales in 2020 [5][6] - In China, the sales growth of Qufei Lianer injection was remarkable, with a year-on-year increase of 186.89% in 2021 [6] Industry Insights - PAH is a rare cardiovascular disease with a high mortality rate, historically referred to as "the cancer of the cardiopulmonary system," with a median survival of only 2.8 years before the advent of targeted therapies [2] - The prevalence of PAH has nearly doubled globally from 1990 to 2021, with an incidence rate of approximately 2.4 per million person-years and a prevalence rate of about 15 per million [1][2] - The five-year survival rate for PAH patients has improved from 34% in 1991 to nearly 57% in recent years, with an average survival time of 6.2 years [2]

Core Viewpoint - The announcement by the company regarding the approval of a new specification for its pulmonary arterial hypertension (PAH) treatment product, Treprostinil injection, highlights its commitment to providing precise treatment options for patients [1][2] Group 1: Product Approval and Specifications - The new specification of Treprostinil injection (20ml:50mg) has received drug registration certification from the National Medical Products Administration, complementing the previously approved specification (20ml:20mg) in March 2023 [1] - Treprostinil is a synthetic prostacyclin analog that promotes vasodilation and inhibits platelet aggregation, making it a first-line treatment for PAH and a foundational drug in targeted therapy combinations [1] Group 2: Company’s Focus and Product Pipeline - The cardiovascular emergency sector is a key focus area for the company, which has nearly 30 products in this segment, with 14 included in the national emergency rescue drug list and 16 in the shortage drug list, positioning the company among the industry leaders in product pipeline quantity [1] - The company has over 20 products under research in the cardiovascular emergency sector, including treatments for rare diseases, with recent approvals for drugs addressing high ammonia levels and Cushing's disease, and ongoing development for other rare disease medications [2]

Core Viewpoint - The approval of the new specification (20ml: 50mg) for the drug Treprostinil by the National Medical Products Administration enhances treatment options for pulmonary arterial hypertension (PAH) patients, providing more precise dosing for clinicians [1][4] Group 1: Product Approval and Market Position - The new specification of Treprostinil injection received its drug registration certificate on September 22, 2023, and is a key medication for treating PAH, being the only prostacyclin analog available for subcutaneous and intravenous administration in China [1] - Treprostinil has demonstrated a stable market performance with annual sales exceeding $100 million, achieving approximately $517 million in global sales in 2020 [2] - The sales of Treprostinil injection in Chinese public medical institutions saw a significant year-on-year increase of 186.89% in 2021 [2] Group 2: Strategic Partnerships and Future Prospects - In November 2024, the company entered into a strategic investment and product cooperation agreement with Shanghai Zhongqiang Pharmaceutical, acquiring approximately 14.42% equity and exclusive commercialization rights for Treprostinil inhalation formulations in Greater China [3] - The agreement also includes global exclusive commercialization rights for Treprostinil injection (excluding UAE, Ireland, and Russia) and its raw materials, as well as for sapropterin tablets for treating phenylketonuria [3] - The global registration process for Treprostinil inhalation and sapropterin tablets is progressing smoothly [3] Group 3: Clinical Impact - The new 20ml: 50mg specification of Treprostinil injection will provide clinicians with greater flexibility in dosing adjustments, better meeting the individualized treatment needs of patients at different stages of the disease [4]

Core Viewpoint - The announcement highlights the approval of a new specification for the drug Treprostinil Injection by the National Medical Products Administration, indicating a significant development for the company and its product line in the treatment of pulmonary arterial hypertension (PAH) [1] Group 1: Product Approval - The new specification of Treprostinil Injection (20ml:50mg) received its drug registration certificate on September 22 [1] - The existing specification (20ml:20mg) was approved for market launch in March 2023 [1] Group 2: Market Position - Treprostinil Injection is listed in the medical insurance catalog and serves as a first-line treatment for PAH [1] - It is the only drug in China that can be administered subcutaneously and intravenously for the treatment of PAH, positioning the company uniquely in the market [1]

Core Viewpoint - The introduction of a new specification for the first-line treatment of pulmonary arterial hypertension (PAH) in China will provide rare disease patients with more clinical medication options [1][2]. Group 1: Product Development and Market Potential - The new specification of 20ml:50mg for the drug Treprostinil injection has been approved by the National Medical Products Administration, complementing the existing 20ml:20mg specification approved in March 2023 [1][7]. - The global PAH market is projected to reach approximately $8.06 billion in 2024, with a compound annual growth rate (CAGR) of 5.3%, and the Asia-Pacific region expected to grow at a CAGR of 13.3% [5]. - Treprostinil, a synthetic prostacyclin analog, has shown significant efficacy and safety in clinical studies, with one-year and four-year survival rates of 88% and 70% respectively [5][6]. Group 2: Company Strategy and Collaborations - The company has entered into a strategic investment and product cooperation agreement with Shanghai Zhongqiang Pharmaceutical, acquiring exclusive commercialization rights for Treprostinil inhalation formulations and injection globally, excluding certain regions [7]. - The company is expanding its product matrix to address unmet clinical needs, focusing on both common and rare diseases, thereby enhancing its market position in the cardiovascular emergency sector [8][9]. Group 3: Clinical and Epidemiological Insights - PAH is characterized by high pulmonary vascular resistance and pressure, leading to severe symptoms and a poor prognosis, with a median survival of only 2.8 years in the absence of targeted therapies [2]. - The incidence of adult PAH is approximately 2.4 per million person-years, with a prevalence of about 15 per million, indicating a significant clinical need for effective treatments [2].

Core Viewpoint - The approval of a new specification for the drug Treprostinil Injection by the National Medical Products Administration of China marks a significant advancement for the company in the treatment of pulmonary arterial hypertension (PAH) [1] Group 1: Product Approval - The new specification (20ml:50mg) for Treprostinil Injection has recently received a drug registration certificate [1] - The previous specification (20ml:20mg) was approved for market launch in March 2023 [1] - Both specifications are included in the medical insurance catalog, allowing for more precise treatment options for clinicians based on patient needs [1] Group 2: Clinical Significance - Treprostinil is a synthetic prostacyclin analog that promotes vasodilation and inhibits platelet aggregation, effectively treating PAH symptoms [1] - Clinical studies have demonstrated the long-term efficacy and safety of Treprostinil, with one-year and four-year survival rates of 88% and 70%, respectively [1] - Treprostinil Injection is a first-line treatment and a foundational drug in targeted combination therapies for PAH [1] Group 3: Market Impact - The approval of Treprostinil Injection alters the market landscape by breaking the previous monopoly of a single product in the domestic market [1] - This development is expected to further reduce the medical burden on PAH patients [1]

Group 1: Product Development and Regulatory Approvals - The company has received a drug registration certificate from the National Medical Products Administration of China for a new specification (20ml:50mg) of its product, Treprostinil injection, used for treating pulmonary arterial hypertension (PAH) [1] - The existing specification (20ml:20mg) was approved for market launch in March 2023, and both specifications are included in the medical insurance catalog, allowing for more precise treatment options for clinicians [1] - The company has reached an equity investment and product cooperation agreement with Shanghai Zhongqiang Pharmaceutical Co., Ltd., which includes acquiring approximately 14.42% equity and exclusive commercialization rights for Treprostinil inhalation formulation in Greater China [2] Group 2: Market Potential and Epidemiology - PAH is a rare cardiovascular disease with an incidence rate of approximately 2.4 per million person-years and a prevalence of about 15 per million, leading to high mortality and disability rates [3] - The global PAH market is projected to reach approximately $8.06 billion in 2024, with a compound annual growth rate (CAGR) of 5.3%, and the Asia-Pacific region expected to grow at a CAGR of 13.3% [3] Group 3: Clinical Efficacy and Treatment Landscape - Treprostinil is a synthetic prostacyclin analog that promotes vasodilation and inhibits platelet aggregation, with clinical studies showing significant long-term efficacy and safety [4] - The one-year and four-year survival rates for patients on Treprostinil monotherapy are 88% and 70%, respectively, indicating a substantial improvement in patient prognosis [4] - The approval of Treprostinil injection has altered the market landscape by reducing the monopoly of single products in the domestic market, potentially lowering the medical burden on PAH patients [4] Group 4: Commitment to Rare Diseases and Innovation - The company is focused on developing treatments for rare diseases, with over 20 products in the pipeline, including those for conditions like N-acetylglutamate synthase deficiency and hyperammonemia [5] - The company aims to address the clinical needs in the rare disease sector, responding to government and societal calls, and is committed to increasing the development of effective treatments for rare diseases [5] - The company emphasizes innovation and advanced technology in product development, aiming to create a global sales network and enhance its international presence [6][7]

Core Viewpoint - The company has made significant progress in the treatment of pulmonary arterial hypertension (PAH) with the approval of a new specification for its drug, which will enhance treatment options for patients [1][4]. Group 1: Product Development and Approval - The company received a drug registration certificate from the National Medical Products Administration for a new specification (20ml: 50mg) of its drug for PAH treatment, complementing the previously approved 20ml: 20mg specification [1]. - The new specifications will allow clinicians to provide more precise treatment plans based on patient needs, marking a major advancement in the rare disease sector of cardiovascular emergency care [1]. - The company has also entered into an equity investment and product cooperation agreement with Shanghai Zhongqiang Pharmaceutical, acquiring approximately 14.42% equity and exclusive commercialization rights for various formulations of its PAH treatment [2]. Group 2: Market Potential and Epidemiology - PAH is a rare cardiovascular disease with an incidence rate of approximately 2.4 per million person-years and a prevalence of about 15 per million, indicating a significant unmet medical need [3]. - The global PAH market is projected to reach approximately $8.06 billion in 2024, with a compound annual growth rate (CAGR) of 5.3%, and the Asia-Pacific region expected to grow at a CAGR of 13.3% [3]. Group 3: Clinical Efficacy and Treatment Landscape - The drug, a synthetic prostacyclin analog, has demonstrated long-term efficacy and safety in clinical studies, with survival rates of 88% and 70% at one and four years, respectively [4]. - The approval of the injection solution has altered the market dynamics, potentially reducing the financial burden on PAH patients [4]. Group 4: Commitment to Rare Diseases - The company is focused on developing treatments for rare diseases, with over 20 products in the pipeline, including those for conditions like N-acetylglutamate synthase deficiency and Cushing's disease [5]. - The company aims to address the significant challenges faced by rare disease patients, where only 5% of such diseases have effective treatments available [5]. Group 5: Innovation and Global Strategy - The company emphasizes innovation and advanced technology in product development, aiming to meet unmet clinical needs and enhance its product pipeline [6][7]. - A strategy of global operational layout and dual-circulation development is being adopted to promote domestic and international growth [6][7].